# Insilico Medicine

Type: Company

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/insilico-medicine
Canonical HTML page: https://gethealthbrief.com/entity/insilico-medicine

## Timeline

- **2026-03-06**: Phase I Milestone — First human subject enrolled and dosed in the Phase I clinical trial.
- **2026**: AI Discovery — Insilico Medicine identifies ISM4808 using its Pharma.AI platform.
- **2025**: Out-Licensing — TaiGen Biotechnology secures rights for the clinical development of the candidate.

## Recent coverage (3 stories)

### How a $2.5B AI Alliance Could Overhaul Drug Manufacturing and Supply Chains
2026-07-15 03:35:58 · Sentiment: Positive · Impact: 7/10 · Sources: 3

The strategic alliance between AI drug discovery firm Insilico Medicine and global CDMO Bora Pharmaceuticals seeks to merge generative AI with manufacturing at scale. With a potential value exceeding $2.5 billion, the partnership could accelerate drug development and strengthen supply chain resilience, directly impacting healthcare delivery and cost structures.
Full story: https://gethealthbrief.com/story/insilico-bora-ai-manufacturing-health-it

### AI‑Powered CNS Drug Discovery Deal Hits $2.5B for Neuroimmune Disorders
2026-06-23 04:57:34 · Sentiment: Strongly positive · Impact: 8/10 · Sources: 2

A breakthrough $2.5B collaboration between AI drug discoverer Insilico Medicine and CNS specialist SK Biopharmaceuticals aims to tackle devastating neuroimmune disorders that have long defied conventional drug development. By combining generative AI with established clinical expertise, the partnership could dramatically shorten timelines and deliver first‑in‑class therapies to patients with conditions like Alzheimer's, multiple sclerosis, and rare neuroinflammatory diseases.
Full story: https://gethealthbrief.com/story/insilico-sk-biopharma-2-5b-ai-drug-discovery-neuroimmune

### Insilico and TaiGen Advance AI-Derived CKD Anemia Drug to Phase I Trials
2026-03-06 12:39:16 · Sentiment: Positive · Impact: 6/10 · Sources: 3

Insilico Medicine and TaiGen have successfully enrolled and dosed the first human subject in a Phase I clinical trial for ISM4808, a novel drug candidate for Chronic Kidney Disease (CKD) anemia. The milestone validates the clinical transition of an AI-discovered molecule under a strategic out-licensing agreement.
Full story: https://gethealthbrief.com/story/insilico-taigen-ckd-anemia-phase-i-milestone

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.